InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.…
InspireMD Announces First U.S. Commercial TCAR Procedures Using the FDA-Approved CGuard® Prime TransCarotid Stent System
InspireMD (NASDAQ: NSPR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 127 employees.
The shares were at 0.5400 USD on 20 November 2026, down 69.8% over 52 weeks. Its 52-week range is 0.4254 USD to 2.220 USD: the price is 75.7% below the high and 26.9% above the low.
Its market capitalisation is 29.23M USD.
InspireMD reports return on equity of -88.4%, an operating margin of -467.7% and revenue down 11.1% year over year.
It holds more cash than debt, a net cash position of 17.54M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 18 March 2027.